Novel Inhibitors of HIV Discovered Among Existing Classes of Pharmaceutical Compounds Indicated for Unrelated Clinical Indications

Author(s): I. I. Kucherov, P. G. Rytik, I. A. Podol'skaya, L. O. Mistryukova, M. O. Korjev

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 11 , 2009

Become EABM
Become Reviewer
Call for Editor


In vitro screening of 307 drugs with various clinical indications (cardiotropic, neurotropic, antibacterial, etc.) has revealed 6 compounds which displayed remarkable antiretroviral activity. Three of these drugs had a tendency to have undesirable side effects and were thus excluded from further consideration. Remaining three, i.e., Xantinol Nicotinate, Tardiferon, and Trental may become valid candidates for inclusion into antiviral regimens such as HAART. In vitro tests have shown that xantinol and trental display synergistic effect with azidothymidine, inhibit the replication AZT-resistant strains of HIV, and have no competing undesirable activities. These compounds should be evaluated in safety studies to determine optimal doses for patients with HIV. If these studies confirm in vitro results these compounds may become valid candidates as safe and affordable means to be added into the arsenal of antiretroviral drugs.

Keywords: Novel Inhibitors, HIV, Clinical Indications, antiretroviral activity, Xantinol Nicotinate, HAART

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Published on: 01 March, 2012
Page: [1187 - 1190]
Pages: 4
DOI: 10.2174/138161209787846856
Price: $65

Article Metrics

PDF: 3